Archive for February, 2018
February 5, 2018
- Despite China’s ban on cryptocurrency, CIIX is positioned to lead the way in cryptocurrency education and awareness for the Chinese-speaking community
- Demand for bitcoin continues to rise despite China’s ban on cryptocurrency
- Company is committed to the education and growth of cryptocurrency and providing innovative ways of making bitcoin more accessible
ChineseInvestors.com, Inc. (OTCQB: CIIX) is continuing its commitment to cryptocurrency education and awareness for the Chinese-speaking community. Its educational services seek to answer the average person’s curiosity while simultaneously providing skilled investors with up-to-date news on digital currency. Using the Chinese language character sets, CIIX provides analysis and education that is accessible to the Chinese-speaking community worldwide. CIIX provides information on how to purchase bitcoin, real-time market commentary and consulting services, as well as advertising and public relations services.
Cryptocurrency is appealing in that it allows investors to diversify their portfolios. This shift away from traditional investment opportunities brings with it an air of excitement. Bitcoin is being exchanged by investors in unregulated offline platforms in an effort to bypass China’s ban (http://cnw.fm/D3Hxq). The scarcity of bitcoin, and the complexity of mining new coins, is part of the draw. Despite a recent post by China’s Communist Party paper bashing bitcoin and insisting that cryptocurrency is a load of hype, demand has continued to rise (http://cnw.fm/jA6Le).
CIIX is committed to raising awareness and education surrounding bitcoin. The company now hosts a daily broadcast from the NYSE, titled ‘Bitcoin MultiMillionaire’, with the intent of educating Chinese-speaking viewers on the most current news in cryptocurrency. In addition, CIIX is committed to bitcoin growth and has installed a bitcoin ATM in the lobby of its headquarters in San Gabriel, California. The Chinese middle and upper class is growing and looking for new ways to diversify their portfolios. ChineseInvestors.com is ready and able to offer them innovative accessibility to cryptocurrency.
For more information, visit the company’s website at www.ChineseInvestors.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
VANCOUVER, British Columbia, Feb. 16, 2018 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the “Units”), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters’ (as defined below) option (the “Offering”). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company (a “Warrant Share”) until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjustment in certain events. Net proceeds from the Offering will be used for exploration and development activities on the Company’s properties and for general corporate purposes.
The Offering was conducted by a syndicate of underwriters led by Canaccord Genuity Corp., as sole bookrunner and lead underwriter, and including GMP Securities L.P. (the “Underwriters”). In connection with completion of the Offering, the Underwriters received a cash commission of 7.0% and options to acquire a number of Units equal to 7.0% of the Units issued in the Offering until February 16, 2020 at an exercise price of $2.10. The Company paid a further cash commission of 3.0% and issued common shares equal to 3.0% of the Units issued in the Offering to a third-party who assisted in facilitating the Offering.
All securities issued or issuable under the Offering are subject to a statutory hold period lasting four months and one day following the closing of the Offering.
About Standard Lithium Ltd.
Standard Lithium’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing resource evaluation on up to approximately 33,000 acres of brine leases located in the Smackover Formation.
Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.
For further information, contact Anthony Alvaro at (604) 240 4793.
On behalf of the Board,
Standard Lithium Ltd.
Robert Mintak, CEO & Director
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain certain “Forward-Looking Statements” within the meaning of applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the anticipated use of proceeds of the Offering, future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations.
Cutting Edge Science Suggests New Molecule Is Capable of Shutting Down Tumor Activity
HOUSTON, TX–(February 15, 2018) – Moleculin Biotech, Inc., (NASDAQ: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that, pursuant to its continued collaboration with MD Anderson it has developed and licensed what it believes, based on preclinical testing, is a major breakthrough in its effort to develop a new cancer treatment that selectively kills highly resistant tumors.
“We believe our unique approach to develop immuno-stimulating STAT3 inhibitors just took a major step forward,” commented Walter Klemp, Chairman and CEO of Moleculin. “Our WP1066 portfolio has already resulted in multiple collaborations with some of the most prestigious cancer centers in the world and now this new discovery could dramatically improve our ability to treat a broader range of the most difficult cancers, and especially pancreatic cancer.”
Dr. Don Picker, Moleculin’s Chief Science Officer, explained, “The scientific community recognizes the potential for small molecule immuno-stimulating STAT3 inhibitors to become a game-changer for treating cancer patients. We believe this discovery may not only dramatically improve our ability to develop and deliver such therapies, it may also help support a new mechanistic understanding of oncogenic transcriptional activity. Specifically, we now have preclinical evidence to suggest we are capable of controlling a process known as ‘ubiquitination’ to block the activated form of STAT3, an important oncogenic transcription factor. The study of the role of ubiquitination in cancer is cutting edge science and appears to hold great promise. And, given the desperate lack of treatment options for indications like pancreatic cancer, we believe clinical researchers across the country have been eagerly awaiting a breakthrough like this.”
“In developing our current lead STAT3 inhibitor, WP1066, for brain tumors, we have focused on its oral bioavailability and brain uptake,” continued Dr. Picker, “but at the same time we have continued our quest to expand this portfolio by the creating alternative inhibitors with increased bioavailability and altered tissue and organ distribution that are not affected by first-pass metabolism. The lead molecule resulting from this new discovery is called WP1732 and it not only appears to share the same key mechanistic properties with WP1066, it has markedly different organ distribution and its dramatically increased solubility makes it ideal for administration via standard IV injection. Importantly, preclinical testing has also shown that WP1732’s properties make it a promising candidate for treating pancreatic cancer, one of the most resistant and deadly forms of cancer.”
“So much has happened in the past few months, it’s important to recap where we are,” added Mr. Klemp. “Moleculin has three potential breakthrough disruptive technologies — (1) Annamycin, an anticancer agent that is active against multidrug resistant tumor cells and has been designed to be non-cardio toxic (unlike currently approved drugs in this class), (2) immuno-stimulating STAT3 inhibitors like WP1066 and, now, WP1732, and (3) WP1122, a metabolic inhibitor that has been shown in preclinical testing to effectively block the energy supply required by cancer cells to function and proliferate. Since our IPO in June 2016, we have accelerated to the point of having two drugs, Annamycin and WP1066, beginning clinical trials in the near term.”
Mr. Klemp concluded, “We are now demonstrating the breadth of our drug pipeline and the benefits of collaborating with world-class cancer research centers. In the AML space, we expect patient dosing either in the United States or Poland to begin with Annamycin yet this quarter and we have begun to work with researchers at MD Anderson on using our immuno-stimulating STAT3 inhibitors to target AML as well. A second clinical trial targeting brain tumors with WP1066 should begin dosing within the first half of the year. In Poland, we are about to request a clinical trial authorization for WP1220 for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL), which we expect will become our third clinical trial this year. WP1220 is our patented STAT3 inhibitor designed to be compatible with topical formulations and was selected based on its preclinical activity in CTCL cell lines and based on the need for better topical treatments for CTCL. Additionally, we just announced positive data for WP1122, our glycolysis inhibitor, in a pancreatic cancer mouse model. Along with the newly licensed discovery of WP1732, this sets the course for establishing the base for two more Investigational New Drug (IND) applications over the coming year and positions us as a leader in developing new approaches for pancreatic cancer. Our highly experienced leadership and expanding team is looking forward to sharing more progress on all of this activity as we move forward into 2018.”
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, a modulator of hard-to-target tumor cell signaling mechanisms intended to attack tumor activity directly while also recruiting the patient’s own immune system. We are also engaged in preclinical development of additional drug candidates, including compounds targeting the metabolism of tumors.
For more information about the Company, please visit http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of Annamycin, WP1066 and WP1220 to demonstrate safety and efficacy in clinical trials and the timing of the commencement of such trials, and the ability of WP1732 and WP1122 to achieve IND status and to demonstrate safety and efficacy in human patients. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
New York, New York–(Newsfile Corp. – February 15, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “Cannabinoids Lead to Marijuana Biotech Boom,” featuring Earth Science Tech, Inc. (ETST).
To hear the NetworkNewsAudio version, visit: LINK
To read the original editorial, visit: LINK
Earth Science Tech’s CBD work is carried out through its subsidiary Cannabis Therapeutics, Inc. (CTI). The company’s CBD oil is 100 percent natural and organic, catering to the environmental concerns common among cannabis users. It is made using a CO2 liquid extraction process that results in a full-spectrum, high-grade hemp CBD oil that has the highest purity and quality on the market.
To keep it in the lead of the CBD market, Earth Science Tech has created partnerships with other research bodies to produce cutting-edge treatments. It is working with the University of Central Oklahoma and DV Biologics Laboratory on research and development projects to enhance the healthcare benefits of its CBD oil. This has positioned the company to take a leadership role in the development of cannabinoid-based pharmaceutical and nutraceutical products. The company holds a provisional application patent for a CBD product for treating breast and ovarian cancers, taking CBD treatments in bold new directions.
One major focus is integrating the CBD molecule with existing generic drug molecules to create more efficient medications that have fewer side effects than the more common approaches. The company is therefore engaged not only in making cannabinoids useful and available to a wider range of patients, but in creating a better experience for existing patients.
About Earth Science Tech, Inc.
Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrate that we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil. For more information, visit the company’s website at www.EarthScienceTech.com
About NetworkNewsAudio
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit: www.NetworkNewsAudio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
February 6, 2018
- Net Element is looking forward to continued growth in 2018
- 2017 held a number of accomplishments, including the company’s strongest balance sheet and a $7.55 million investment
- Over the past year, Net Element has produced important product launches in the U.S. and internationally
Net Element, Inc. (NASDAQ: NETE) is looking forward to continual development and delivery of innovative payment solutions in 2018 and beyond. According to a recent press release (http://nnw.fm/8aDOe), last year provided the company with its strongest balance sheet on record. In 2017, Net Element re-focused business initiatives internationally and saw organic growth across all categories. In a news release, CEO Oleg Firer said that the company’s leadership team is very pleased with the progress made and looks “forward to significant accomplishments in 2018 to include the addition of blockchain technology that will act as a framework for an unlimited number of value-added services.” According to Firer, the future looks promising as the company remains focused on the execution of its long-term objective “to create a single, international on-boarding and transaction processing platform across payments ecosystems.”
In 2017, the company received a $7.55 million institutional investment, supporting continued organic growth and ensuring full scalability of its platform, as well as blockchain-focused developments. Deloitte’s 2017 Technology Fast 500™ ranked Net Element as one of the fastest-growing companies in North America. The year before, 2016, South Florida Business Journal ranked Net Element as one of the fastest-growing technology companies. When Hurricane Irma hit, the company was ready and able to support affected Florida SMB merchants with free mobile point-of-sale credit card readers. Net Element works to provide virtually seamless payment solutions and powerful problem-solving expertise to the small to medium enterprises it serves. The $7.55 million investment has put the company in position to continue achieving organic growth as it moves forward with innovative blockchain developments.
The company competes in highly competitive market segments using innovative technology at the core of its products. In 2017, Net Element launched several successful products to better the user experience. The products launched exclusively in the United States included a same-day ACH payment processing solution, a zero-fee processing program for SMB merchants and PayOnline’s support for electronic commerce. In Russia, the company launched Apple Pay support. Additional product launches included loyalty programs for merchants; a payment acceptance module for Telegram, Viber and Facebook; VK instant messenger apps; a comprehensive point-of-sale program during Unified Payments’ 2017 Launch Series at the Northeast Acquirers Association event; and an ISO incubator program for certified resellers of Unified Payments. NETE also expanded payment modules to include Prominent InSales.
Net Element has goals in the United States and internationally. In the U.S., it seeks to grow transactional revenue. By using blockchain technology and Aptito, a cloud-based, restaurant and retail point-of-sale solution, the company aims to grow transactional revenue. Internationally, it leverages an omni-channel platform, delivering flexible offerings to emerging markets.
For more information, visit the company’s website at www.NetElement.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
February 15, 2018
- The tide of cannabis legalization continues to rise
- Medical cannabis market on pace to hit $56 billion in seven years
- Company’s proprietary technology improves the bioavailability of cannabinoids
With the passage of laws permitting medicinal use of cannabis in at least 32 U.S. jurisdictions and Canada, producers of cannabinoids for medical purposes are racing to improve delivery methods for their formulations. Cannabinoids, such as cannabidiol (CBD), are hydrophobic (literally, afraid of water). In practice, this means they do not dissolve or emulsify readily in water, which may seem to pose a problem, since, by composition, the human body is more than half water. Yet, paradoxically, for a drug to be readily absorbed, it must be largely hydrophobic, yet not completely so. It must, to some extent, dissolve in water. As a result, new, patented technology from Pressure BioSciences Inc. (OTCQB: PBIO) may provide the ideal transport for CBD and other cannabinoids. PBIO’s Ultra Shear Technology (“UST”) has the capacity to develop water-soluble nanoemulsions that can be employed to improve the bioavailability of cannabinoids.
Emulsions are mixtures of two or more liquids (e.g., oils in water) that cannot be blended into each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in multiple everyday products, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Nanoemulsions have been shown to have improved absorption while providing higher bioavailability, greater stability and other advantages, when compared to the standard, much larger macro- and micro-emulsions.
Nanoemulsions offer an advanced mode of drug delivery that’s expected to improve the bioavailability of a wide range of active agents. These nano-sized emulsions, in which two immiscible liquids are usually combined to form a single phase by means of an emulsifying agent that combines surfactant and co-surfactant, typically have droplet sizes that fall in the 20–200 nanometer range. It would take 10 million nanometers to cover a length of one centimeter (about 0.4 inches).
Interestingly, PBIO believes that its patented UST may be able to make commercial-scale nanoemulsions that would require far less emulsifying agents than current methods, perhaps even none. Emulsifying agents are chemicals; some are natural, some are not. With consumer demands for non-additive natural products, the availability of nanoemulsions that require little or no chemical emulsifiers should be well received by consumers and manufactures alike, and rewarded by shareholders.
Late last year, PBIO announced a partnership with Phasex Corporation. The aim of the collaboration is to combine PBIO’s patented UST and Phasex’s supercritical fluid (“SCF”)-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. Phasex is a pioneer in the development of SCF-based toll processors, which are used for extracting, purifying, recrystallizing and fractionating a wide range of polymers, natural extracts and other chemicals.
Complementing Phasex’s SCF extraction technology with PBIO’s UST makes a great deal of commercial sense. Currently, there is a market for new methods of turning hydrophobic extracts into stable, water-soluble formulations. UST offers the potential to solve that problem by producing stable nanoemulsions of oil-like products in water. The range of commercial applications is extensive and includes inks, industrial lubricants, cosmetics, pharmaceuticals and nutraceuticals, as well as medically important plant oil extracts such as CBD. UST utilizes ultra-high pressure-driven fluid dynamic shear forces, combined with controlled temperatures, to engender homogenization.
Data from scientific studies indicate that nanoemulsions of nutraceuticals and pharmaceuticals may exhibit improved absorption, higher bioavailability, greater stability and lower levels of stabilizing additives (surfactants) when compared to the larger droplet sizes resulting from current emulsion processes. Because of these significant advantages, nanoemulsions are currently the focus of many research efforts worldwide. In this field, the PBIO-Phasex joint venture is poised to break new ground. Combining Phasex’s SCF extraction methodology with PBIO’s disruptive drug delivery technology may signal the genesis of an entirely new paradigm in therapeutic treatments.
The global medical marijuana market is set to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. As it expands, the demand for enabling medical technologies, such as UST, is set to rise. PBIO, it seems, is about to thrive in the brave new world of cannabis liberalization.
For more information, visit the company’s website at www.PressureBioSciences.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
The gaming industry has come a long way since the days of plugging quarters into a PAC-MAN or Atari machine in video arcades. Gaming has grown to become the highest grossing entertainment product of all time. That evolution happened incrementally- Xbox gamers started joining online groups and building virtual relationships — forging bonds through love of the game. The stimulus was about tapping into a mental agility- and the reward was reaching the next level of the game.
New games have appeared in the gaming galaxy — CryptoKitties exploded onto the gaming scene in 2017, and on December 2, the high selling cat was sold for 246.9255 ETH ($117,712 USD) on that day. Tron (TRX) Dogs, the kitties’ more masculine counterpart, had soared to a $16 billion market cap in early January.
Blockchain-focused venture builder Victory Square Technologies Inc (OTC:VSQTF) (CSE:VST) (FWB:6F6) is becoming more active in the gaming space, and aims at innovating virtual economies. Leading companies that could potentially move into this direction are Western Union Company (NYSE: WU), HIVE Blockchain Technologies Ltd. (OTC: HVBTF), and HashChain Technology Inc. (OTCQB: HSSHF).
Blockchain-based cryptocurrencies have undoubtedly penetrated the gaming market, and the paradigm shift is now there are more options and new forms of rewards and upgrades for gamers.
The World of Warcraft is the juggernaut of the industry — raking in over $10 billion in revenue. Imagine how much more revenue this multi-player game could earn on in-game purchases with blockchain technology. Blockchain could potentially take gaming from a $108 billion industry to a $trillion industry.
Yesterday, Victory Square Technologies announced the company has acquired 100 percent of all issued and outstanding shares of Vancouver-based mobile games developer V2 Games Inc. for $2 million CAD.
V2 Games started as a game development and publishing studio, and was the first Canadian Company to license the iconic PAC-MAN IP for a mobile game. The company has an operating history of licensing large IPs, including PAC-MAN, Hello Kitty, the NFL and the NBA. Fueled by its success in the mobile gaming market, V2 Games started investing its returns into other companies in the gaming ecosystem.
V2 Games’ portfolio of companies includes Kung Fu Factory, Immersive Tech and Nyan co. In January, V2 Games launched the Future Fund – a $10 million seed fund for gaming ventures. The fund is for strategic investments into the video game vertical, and targets game ventures, esports, as well as start-ups that have a strong use-case for leveraging blockchain within the gaming ecosystem. While the fund will have a global outlook, 50 percent of the fund will be reserved for investments in Canadian video gaming startups.
“Just as we’ve committed to partnering with high quality entrepreneurs and management teams that drive long-term shareholder value, V2 Games supports top tier teams in the gaming industry with a view to unlocking their potential by providing them with seed capital and the necessary strategic expertise needed to scale their gaming ventures,” said Victory Square CEO Shafin Diamond Tejani.
Tejani added that post-acquisition, Victory Square will integrate V2 into the company’s growing portfolio of disruptive technology investments.
Sam Chandola, CEO of V2 Games, said the acquisition is in line with the company’s core competency of identifying early investments in gaming assets, and that it also puts V2 ahead of schedule in its pursuit to be a key strategic investment hub.
This merger marks a meeting of great minds, and surely sets the stage for future disruptive investments as this entrepreneurial team sets its goal on discovering the gaming galaxy’s next Cryptokitties and Tron Dogs.
Comparables:
DMG Blockchain Solutions Inc. (TSX-V: DMGI)
DMG Blockchain Solutions is focused on managing and developing solutions to monetize the blockchain ecosystem. It intends to become a leader in Bitcoin mining, mining as a service (MaaS), forensics, and diversified blockchain platform development. Recently, DMG acquired Blockseer, a U.S.-based company that provides the analytics tools for blockchain data.
HashChain Technology Inc. (OTCQB: HSSHF)
HashChain Technology is a blockchain company focused on mining various types of cryptocurrencies in North America using its proprietary technology. The company has already signed purchase orders for 5,000 mining rigs. Last month, it received another 770 rigs from China.
Western Union Company (NYSE: WU)
Colorado-based Western Union is the world’s largest money transfer service. The company has started trials using Ripple’s enterprise blockchain for its transactions. According to the company, it will continue to explore blockchain applications for its business.
HIVE Blockchain Technologies Ltd. (OTC: HVBTF)
HIVE Blockchain is currently operating as a cryptocurrency mining firm through an established partnership with Genesis Mining Ltd. Recently, HIVE started its Ethereum mining operations in Sweden. The company has raised over $200 million since last September to finance its business.
For a more in-depth look into CSE:VST, view the full report.
Legal Disclaimer/Disclosure:
This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Baystreet.ca assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Baystreet.ca has been compensated one thousand eight hundred dollars for its efforts in distributing the Victory Square article. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.
Montrouge, France, February 14, 2018
DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) today announced that the U.S. Food and Drug Administration (FDA) has agreed that the available efficacy and safety data for Viaskin Peanut supports the submission of a Biologics License Application (BLA) for the treatment of peanut allergy in children four to 11 years of age.
The FDA provided written responses to the clinical pre-BLA meeting package submitted by the Company, which reflect agreement on the content of the clinical module of the BLA for Viaskin Peanut. DBV remains on track to submit its BLA in the second half of 2018.
“We are pleased with this positive step forward in our progress towards potential approval of Viaskin Peanut, and appreciate the feedback we received from the FDA supporting submission of our BLA,” said Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies. “There are approximately one million children in the U.S. diagnosed with this life-threatening disease, and we look forward to continue working with the agency to address this urgent unmet medical need.”
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the potential of Viaskin Peanut and the regulatory posture of Viaskin Peanut. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the products of the Company have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and the risk that historical clinical results in one patient population may not be predictive of future clinical trial results in different patient populations. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2016 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.
DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
sara.sherman@dbv-technologies.com
DBV Media Contact
Roberta Di Giorgio
Senior Director, Corporate Communications
+1 917-612-2861
roberta.digiorgio@dbv-technologies.com
Fossil Group Inc (NASDAQ:FOSL) stock skyrocketed after the company topped revenue and earnings estimates for the fourth quarter. Additionally, its move to become an e-commerce/wearable-tech brand enhanced investor’s confidence in its future fundamentals.
Fossil share price rose almost 67% in early trading on Tuesday; shares briefly hit $17 before retreating to $14 a share.
Solid Q4 Results For Fossil Group Inc
Fossil revenue topped the consensus estimate by $31 million, while earnings exceeded analysts’ estimates by $0.27 per share.
Additionally, the company has achieved several major milestones, aimed at accelerating its strategic objective of moving the revenue base to new channels. The company has been following four key strategic goals:
- Driving growth in wearable’s across its portfolio of powerful brands
- Leveraging its scale to lower supply chain costs
- Increasing its digital capabilities
- Continuing the transformation of its business through New World Fossil.
Its business strategies are working; wearable sales doubled to over $300 million in Q4, accounting for 14% of total watch sales. The sales for Michael Kors watches improved in the latest quarter, and Armani watches posted double-digit growth in sales.
Its CEO said, “We introduced a number of new hybrid and display smartwatches across 14 brands and believe the continuation of this effort, combined with the innovation we are introducing across our traditional styles, has us poised for stabilization and growth over time.”
On the other hand, Fossil management substantially expanded its digital presence – allowing the company to generate 31% Y/Y growth in e-commerce sales in the fourth quarter.
>>GNC Holdings: Bullish Bets Soar
The Stock is Set to hit $25, Analysts Say
KeyBanc has lifted FOSL stock price target to $25 from the earlier price target of $15. Several other analysts, including L&F Capital Management and DTF Capital, expect steady growth in FOSL share price.
Overall, investors are admiring the company’s strategy of reducing the cost structure, while moving its business model towards higher growth businesses. Fossil management lowered its expenses by $95 million last year; expecting to reduce operational costs by $200 million by the end of 2018
Established mobile games studio is the latest addition to the VST portfolio of technology companies spanning core competencies in Blockchain, Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film
VANCOUVER, BRITISH COLUMBIA, CANADA (February 14, 2018) – Subject to all requisite regulatory approvals, Victory Square Technologies Inc. (“Victory Square” or the (“Company”) (CSE:VST) (OTC:VSQTF) (FWB: 6F6) will acquire 100% percent of all issued and outstanding shares of V2 Games Inc. (“V2 Games”), an established mobile games studio with a track record of highly-rated entries on the Apple Store listings, for $2,000,000 CAD in total consideration (the “Purchase Price”).
Pursuant to a definitive share purchase agreement to be executed between the Company and the shareholder(s) of V2 Games (the “Share Purchase Agreement”), the Purchase Price will be paid and satisfied by the Company through the issuance of 1,030,928 common shares in the capital of the Company (the “Consideration Shares”) to the shareholder(s) of V2 Games at a deemed issue price of $1.94 per Consideration Share. The deemed issue price represents the closing price of the common shares of the Company on the Canadian Securities Exchange at the end of trading on February 13, 2018, the trading day preceding this news release announcing the acquisition, less a discount of 10%. In accordance with the terms of the Share Purchase Agreement, the Consideration Shares shall be subject to resale restrictions, which permit 8% of the Consideration Shares to be eligible to be free trading four months from the date of issuance to satisfy the statutory hold period and a further 8% every three months thereafter until the final balance of Consideration Shares is eligible to be free-trading in approximately three years’ time. The Share Purchase Agreement also contains standard representations, warranties and covenants for transactions of this nature.
“Given the full and total philosophical alignment between our companies, we are of course excited and proud to announce the acquisition of V2 Games, a leading mobile games developer based in Vancouver, Canada,” said Victory Square Chief Executive Officer Shafin Diamond Tejani. “Just as we’ve committed to partnering with high quality entrepreneurs and management teams that drive long-term shareholder value, V2 Games supports top tier teams in the gaming industry with a view to unlocking their potential by providing them with seed capital and the necessary strategic expertise needed to scale their gaming ventures. As entrepreneurs ourselves, we are impressed with the V2 Games model, along with the depth of knowledge of the management team.”
Started as a game development and publishing studio, V2 Games was the first Canadian company to license the iconic PAC-MAN IP as a mobile game. The company has a rich operating history of licensing large IPs, including PAC-MAN, Hello Kitty, the NFL and the NBA. Fueled by its success in the mobile gaming market, V2 Games evolved as a company and began investing its returns into other companies within the gaming space.
“This acquisition not only allows us to maintain our core competency of identifying early investments in gaming assets, but firmly puts us ahead of schedule in our pursuit to be a key strategic investment hub with which entrepreneurial video game teams will continue to place their faith in order to bring their creations to life,” said Sam Chandola, the award-winning CEO of V2 Games. “Through Victory Square’s expertise in the public markets, we will now be able to offer top-tier opportunities in the gaming market to retail investors, while also leveraging the strength of the public markets to facilitate new financing opportunities for the gaming industry.”
Apart from a focus on the established western gaming market, V2 Games has also made significant investments in emerging markets in the gaming industry, with the company having setup subsidiary operations in India as early as January 2016.
“Post-acquisition, Victory Square will seamlessly integrate V2 into our fast-growing portfolio of disruptive technology investments,” said Tejani. “Through a combination of management, legal, operational, and marketing expertise, we will assist the V2 management team in accelerating their business and positioning them as an emerging leader in the mobile games market.”
V2 Games CEO Chandola is also a recipient of many entrepreneurial awards, including the BC Business Top 30 under 30 award (2014), RBC Top 75 Canadian Immigrant (2015), and the TMX Next 150 (2017). With a keen eye on the future, he is also at the forefront of exploring exciting new opportunities in the world of gaming brought by new technologies such as Blockchain.
“Victory Square’s experience as an early promoter of Blockchain will help support our new and exciting initiatives to explore the intersection of Gaming and Blockchain,” added Chandola. “V2 Games is one of the first traditional gaming companies that is investing heavily in Blockchain, and Victory Square is an ideal partner in that regard.”
Recent V2 Games’ investments include Flow, an equity crowdfunding platform for games powered by Blockchain, and Shape Immersive, an AR Blockchain company that develops state of the art products that bridge the experience between the physical and virtual worlds.
For further information about the Company, please contact:
Investor Relations Contact – Prit Singh
Email: prit@victorysquare.com
Telephone: 905-510-7636
Media Contact – Howard Blank, Director
Email: howard@victorysquare.com
Telephone: 604-229-3594
ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square Technologies is a blockchain-focused venture builder that funds and empowers entrepreneurs to implement innovative blockchain solutions. Victory Square portfolio companies are disrupting every sector of the global economy including Virtual Reality, Artificial Intelligence, Personalized Health, Gaming and Film. Victory Square has a proven process for identifying game-changing entrepreneurs and providing them with the partners, mentorship and support necessary to accelerate their growth and help them scale globally. For more information, please visit www.victorysquare.com.
ABOUT THE CANADIAN SECURITIES EXCHANGE (CSE)
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets.
FORWARD-LOOKING INFORMATION
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Victory Square. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square, including future plans. Although Victory Square believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Victory Square can give no assurance that they will prove to be correct. Forward- looking statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
ISS High Pressure Optical Cell Integrated with PBI Automated High Pressure Instrument: Combination Results in Unique Analytical System with Potential to Significantly Improve and Enhance Biopharmaceutical Drug Discovery and Development
SOUTH EASTON, MA / February 14, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments and related consumables for the worldwide life sciences industry, and ISS, Inc., a designer and manufacturer of advanced scientific instrumentation for over 30 years, today announced a two-year, global co-marketing and distribution agreement.
Thousands of scientists worldwide routinely use a powerful analytical method called optical spectroscopy to generate information on the composition of biological molecules, such as proteins, RNA, and DNA. Information obtained is used for many purposes, including the design and development of new drugs, diagnostics, vaccines, and disease preventive strategies. Interfacing innovative new capabilities with the optical spectrometer offers the potential to generate more, sometimes even critical information for the scientist.
High pressure optical spectroscopy is increasing in popularity because it offers a unique and very effective way to look at molecular interactions. Unlike chemicals, which take time to mix and interact with a biological sample and whose use often produces uncontrollable irreversible changes, high pressure is instantaneous and homogeneous and the line between reversibility and irreversibility can be better controlled by controlling the amount and duration of the applied pressure. These features help research scientists understand how biological molecules interact and function – information that can be critical to the discovery and development of new and improved drugs and diagnostics.
Dr. Ben Barbieri, President of ISS, said, “ISS is a worldwide, leading provider of high pressure optical cell systems that can be interfaced directly to our spectrometers or utilized as stand-alone units with non-ISS instruments. The pressure required for the optical cell is currently generated by a manual, crank-operated, non-automatable pressure generator. We believe that replacing this manual crank pressure generator with the computer controlled HUB 440/880 pressure instruments from PBI could result in the ability to visualize biochemical reactions as they are happening in the pressure cell. The PBI pressure generators will also facilitate automated and significantly faster data collection. Such systems could potentially have a significant and far-reaching impact on drug development and other important areas of biomedical research worldwide.”
Dr. Alexander Lazarev, Vice President of R&D for PBI, said, “Our pressure-generating instruments are widely used to control enzymatic activity and manipulate protein conformation in biomarker discovery, quality control of biopharmaceuticals, and biophysical studies of protein drug targets. Currently, our customers can only visualize irreversible molecular changes remaining after samples are retrieved from a pressure chamber. However, interfacing the PBI HUB 440/880 pressure generators with the ISS high pressure optical cell system will allow scientists to visualize and measure pressure effects on molecular interactions and protein conformation as the reactions are taking place in the optical cell – in real time. This novel capability should help scientists better understand how proteins function and interact with other biomolecules, which is critically important in the development of better, more effective diagnostics and pharmaceuticals.”
Dr. Nate Lawrence, Vice President of Marketing and Sales for PBI commented, “We are very pleased to enter into this co-marketing and distribution agreement with ISS. The unique combination of PBI’s high pressure generators and ISS’s high pressure optical cell system is expected to greatly benefit scientists in academic institutions, industry, and government who study biological samples and processes at the molecular level.”
Dr. Lawrence continued, “This new ISS/PBI instrument system will be unveiled at the annual Biophysical Society Meeting (BPS), which begins on February 17th in San Francisco, CA. PBI and ISS have exhibit booths at the meeting, where the new instrument system will be showcased, and its cutting-edge applications presented to the more than 7,000 scientists expected to attend. Both companies will share their extensive customer contact lists to broadly promote this powerful combination of technologies to scientists worldwide, which we believe will result in increased sales in 2018 and beyond.”
About ISS, Inc.
Since 1984, ISS has been committed to the design and development of innovative, highly-sensitive scientific instrumentation for research, clinical, and industrial applications. ISS instrumentation is used by scientists working in the life sciences, drug discovery, material sciences, and basic physical-chemical research applications. ISS instruments have been installed in university, government, and industry laboratories worldwide. In the United States, customers include – among others – academic institutions, pharmaceutical and biotech companies, the Mayo Foundation, the VA Administration, the National Institutes of Health, Oak Ridge National Laboratories, and the National Aeronautics and Space Administration (NASA).
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward-Looking Statements
Statements contained in this press release regarding PBI’s intentions, hopes, beliefs, expectations, or predictions of the future are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Investor Contacts:
Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.
Nathan P. Lawrence, Ph.D., VP of Marketing and Sales (508) 230-1828 (T)
Beniamino Barbieri, Ph.D., President ISS, Inc. (217) 359-8681 (T)
For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
February 14, 2018
- Update highlights proposed acquisitions, product development and growing IP portfolio
- Three new patent filings join established global rights to other patented technologies
- Innovative transdermal delivery technology increases bioavailability of cannabinoids
- Global cannabis market projected to reach $31.4 billion by 2021
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has provided investors an update covering a number of recent achievements and ongoing activities, including the company’s proposed acquisitions of ERS Holdings, LLC and Thrudermic, LLC; its ongoing product development efforts; its growing IP portfolio; its termination of a previously announced standstill agreement; out-licensing of its IP; and its engagement of an established European distribution partner (http://cnw.fm/sB649). In a news release, Dr. Patrick Frankham, CEO of Pivot, stated, “We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes.”
Based in Vancouver, Canada, Pivot Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using proprietary drug delivery platform technologies. By developing and commercializing a number of pharmaceutical-grade formulations for cannabinoid-based consumer health care products, Pivot Pharmaceuticals is positioning itself to capitalize on the impressive growth of the cannabis market. According to market research company Brightfield Group, the marijuana market will experience a CAGR of 60 percent to reach $31.4 billion by 2021 (http://cnw.fm/8Kg16).
As part of its overall growth strategy, Pivot Pharmaceuticals recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office, according to a company press release (http://cnw.fm/J3CsB) issued on February 1, 2018. Its three patents cover:
- Transdermal nanotechnology delivery of cannabis using patches and creams
- Mucus topical cannabis delivery through buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository
- Inhalation delivery of cannabis for topic or systemic applications
These latest provisional patent filings join an established number of global rights to topical, oral, transdermal, food and beverage patented technologies that Pivot has already secured.
A case in point is Pivot’s recent acquisition of the BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids. Oral delivery of cannabinoids can produce inconsistent absorption efficiencies and unfavorable side effects, while topical delivery technologies often suffer from weak formulation issues. By contrast, transdermal delivery has greater potential to produce a more favorable outcome without the negative side effects and absorption issues. Another benefit of transdermal delivery is that it enables patients to apply medication over a prolonged period with fewer side effects than with other methods of delivery. The BiPhasix™ delivery system, thoroughly tested in clinical trials approved by the FDA and EMA, was demonstrated to enhance the bioavailability of drugs and to improve clinical outcomes.
Pivot Pharmaceuticals also created subsidiary Pivot Green Stream Health Solutions Inc. to focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream will develop natural cannabinoid-based health products that qualify for the Natural Health Product (NHP) designation conferred by Health Canada.
In addition, Pivot has acquired the global rights from Solmic GmbH for the development and commercialization of the Solmic Solubilization Technology Platform. This formulation technology provides significantly higher bioavailability of active ingredients while masking unpleasant tastes and smells. This oral delivery platform greatly increases uptake of fat-soluble ingredients from the gut into the blood system, resulting in increased bioavailability.
The company has several products in its development pipeline which target cancer supportive care, pain and inflammation, dermatology and eye disease. They include PGS-N005, a cannabinoid-based topical cream to treat female sexual dysfunction. This formulation will treat hypoactive sexual desire disorder, aimed specifically at peri-menopausal, menopausal and post-menopausal women with a decline in sexual desire and response. It is estimated that up to 63 percent of women in the United States may be affected by this disorder, with the female sexual dysfunction market estimated to exceed $4 billion.
Pivot Pharmaceuticals has a seasoned management team with extensive clinical, product development, commercial and financial experience. The company has positioned itself to be a crucial vertical in the cannabis industry, with a focus on biotechnological development. As part of its business strategy, Pivot works with licensed producers (LPs) and licensed dealers (LDs) to bring new therapies to the market.
For more information, visit the company’s website at www.PivotPharma.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
February 14, 2018
- ETST intends to make 2018 its breakout year, seeks uplisting to the OTCQB Venture Market
- Company manufactures using European CO2 extraction process with organically grown, unfiltered industrial hemp
- ETST engages a new distributor to market revamped product line to major retailers, also adds several new members to its executive team
On February 13, Earth Science Tech, Inc. (OTC: ETST) officially launched its High Grade Full Spectrum Cannabinoids products and a corresponding marketing strategy, as the company detailed in a recent news release (http://nnw.fm/5NXIi). Additionally, it signed a distribution agreement with Mr. Checkout to market its revamped product line to major retailers and stores, such as Walmart, Target and Walgreens (http://nnw.fm/bBOg5).
The revamped line consists of industrial hemp product formulated as a cannabinoid complex, which is naturally occurring in the industrial hemp plant and is rich in terpenes and saponins. The company’s products are mixed, bottled and packaged in the U.S., and reorders are currently being accepted online. The line appears in modern and edgy packaging.
Based in Florida, ETST markets high-purity, high-grade hemp cannabidiol (CBD) oil. It is 100 percent natural and organic. The company has three wholly-owned subsidiaries: Earth Science Pharmaceutical markets low-cost, non-invasive medical devices for the detection of sexually transmitted diseases (STDs); Cannabis Therapeutics is an emerging biotechnology company; and KannaBidioiD focuses on the recreational space with its hemp and Kanna blends.
ETST recently strengthened its core executive team (http://nnw.fm/2BRYy) through the addition of Jill Buzan as chief sales officer, Wendell Hecker as chief financial officer and Gabriel Aviles as chief learning officer. The company expects the moves to foster bottom line growth in 2018.
In a news release, Nickolas S. Tabraue, COO and president of ETST, said, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor, Mr. Checkout, we are on track for a record-setting revenue month.” He added that the company intends to make 2018 its breakout year, for which it is laying a strong foundation in the first quarter.
The company also announced that it has completed the paperwork for its uplisting to the OTCQB Venture Market later this year.
For more information, visit the company’s website at www.EarthScienceTech.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
— Consistent Improvements Sustained Across All Assessments of Muscle Function Through 48 and 60 Weeks of Edasalonexent Treatment in MoveDMD® Trial —
— Single Global Phase 3 Trial Expected to Begin in First Half of 2018 —
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new positive efficacy and safety results showing preservation of muscle function and sustained disease-modifying effects in boys with Duchene muscular dystrophy (DMD) in the MoveDMD trial open-label extension following 48 and 60 weeks of treatment with edasalonexent. Consistent improvements in all assessments of muscle function were observed after more than a year of oral 100 mg/kg/day edasalonexent treatment compared to the rates of change in the pre-specified control period for boys prior to receiving edasalonexent treatment. Additionally, supportive changes in non-effort based measures of muscle health were seen, with significant longer-term reductions in muscle enzymes and C-reactive protein (CRP), supporting the durability of edasalonexent treatment effects. Edasalonexent continued to be well tolerated with no safety signals observed in the trial. These data will be presented on Saturday, February 17, 2018, at 14:15 CET at the XVI International Conference on Duchenne and Becker Muscular Dystrophy in Rome, Italy, and detailed at future scientific conferences.
Catabasis plans to initiate a single global Phase 3 trial with edasalonexent in patients with DMD regardless of mutation type in the first half of 2018 with top-line results expected in 2020. Edasalonexent is a potential oral foundational therapy that is being developed for all patients affected by DMD.
“We are thrilled to see this preservation of muscle function and substantial slowing of disease progression in boys following more than a year of edasalonexent treatment. This effect has the potential to be extremely impactful for boys affected by Duchenne,” said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. “Building on the results previously reported for edasalonexent treatment in patients up to 36 weeks, these new data at 48 and 60 weeks show that edasalonexent continued to slow progression of the disease. We look forward to advancing edasalonexent in a single global Phase 3 trial later this year with the goal of improving the quality and length of life for those affected by Duchenne.”
“As this study matures and we see the effect of edasalonexent treatment through 48 and 60 weeks, it is compelling that all of the assessments of muscle function are demonstrating stabilization at an age when boys with DMD have a predictable decline,” said Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System and a Principal Investigator for the study. “Clinically meaningful changes are observed here. The coherence of these data is very promising and I look forward to continuing to investigate edasalonexent in the Phase 3 trial as a potential therapy for the many boys affected by this devastating disease.”
In Phase 2 and the open-label extension of the MoveDMD trial, a preservation of muscle function and slowing of DMD disease progression was seen in boys treated with edasalonexent compared to the rates of change during the control period prior to receiving edasalonexent. Through 60 weeks of treatment, the 100 mg/kg/day treatment group showed consistent and clinically meaningful improvements in rates of decline compared to rates of change during the control period across all four assessments of muscle function: the three timed function tests (10-meter walk/run, 4-stair climb and time to stand), as well as the North Star Ambulatory Assessment (NSAA), an integrated global assessment of muscle function. Control period changes were measured prior to boys receiving edasalonexent, either prior to Phase 2 or during Phase 2 prior to treatment in the open-label extension for those in the placebo group, for time periods averaging 39 weeks. In the 100 mg/kg/day treatment group, 16 boys commenced edasalonexent either at the beginning of Phase 2 or at the beginning of the open-label extension. At the time of this most recent open-label extension data analysis on functional assessments, all 13 boys continuing to participate had received 100 mg/kg/day for 48 weeks and 8 had reached 60 weeks of 100 mg/kg/day edasalonexent treatment.
Additional supportive measures of muscle health also reinforce positive edasalonexent treatment effects in the 100 mg/kg/day treatment group. Four muscle enzymes (creatine kinase, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase) were significantly decreased compared to baseline following edasalonexent treatment at 12 weeks and later time points through 60 weeks (p<0.05), consistent with the ability to slow muscle degeneration and improve muscle integrity. Biomarker results showed that CRP was significantly decreased with edasalonexent at 12, 24, 36 and 48 weeks compared to baseline in the 100 mg/kg/day treatment group (p≤0.001). CRP is a well-characterized blood test marker that provides a global assessment of inflammation, and CRP is elevated in boys affected by DMD. The significant decrease observed in CRP supports the biological activity of NF-kB inhibition by edasalonexent treatment decreasing inflammation.
Edasalonexent continued to be well tolerated with no clinical safety signals observed to date. The majority of adverse events (AEs) have been mild in nature with no serious AEs. The most common related AEs were gastrointestinal, primarily mild and transient diarrhea. Boys with DMD in this age range typically have resting tachycardia, a heart rate that exceeds the normal resting rate, and the heart rate of the boys treated with edasalonexent decreased toward age-normative values during treatment.
Catabasis plans to initiate a single global Phase 3 trial in DMD in the first half of 2018 to evaluate the efficacy and safety of edasalonexent for registration purposes. The design of the randomized, double-blind, placebo-controlled trial has been informed by discussions with FDA and EMA. The Phase 3 trial is expected to have many key elements in common with the Phase 2 trial, including the patient population and functional endpoints. Catabasis anticipates enrolling approximately 125 patients between their 4th and 7th birthday who have not been on steroids for at least 6 months. Boys on a stable dose of eteplirsen may be eligible to enroll. The primary efficacy endpoint will be change in the North Star Ambulatory Assessment score after 12 months of treatment with edasalonexent compared to placebo. Key secondary endpoints are planned to include age-appropriate timed function tests. Assessments of growth, cardiac and bone health are also planned to be included. Catabasis expects to report top-line results from this trial in 2020.
About the MoveDMD Trial
The MoveDMD trial is investigating the safety and efficacy of edasalonexent in steroid-naïve boys enrolled at ages 4 – 7 affected with DMD (any confirmed mutation). The trial is comprised of three parts – Phase 1, Phase 2 and open-label extension. Phase 2 was a randomized, double-blind, placebo-controlled 12-week portion with 31 ambulatory boys across a range of dystrophin mutations. The 12-week MRI T2 primary endpoint for treated boys compared to placebo was directionally positive although not statistically significant. The open-label extension evaluated longer term safety and efficacy using pre-specified analyses comparing the rates of change in boys receiving edasalonexent treatment and prior to treatment. In the Phase 2 and open-label extension of the MoveDMD trial, edasalonexent substantially slowed DMD disease progression in boys on 100 mg/kg/day through 60 weeks of treatment. Across all assessments of muscle function, consistent improvements were observed in the rate of decline after 12, 24, 36, 48 and 60 weeks of oral 100 mg/kg/day edasalonexent treatment compared to the rate of change in the control period for boys prior to receiving edasalonexent treatment. Statistically significant improvements were also seen across available non-effort based measures of muscle health. In the 100 mg/kg/day treatment group, 16 boys commenced edasalonexent either at the beginning of Phase 2 or at the beginning of the open-label extension. Edasalonexent was well tolerated with no safety signals observed in the trial. Catabasis expects to present additional data at scientific meetings in 2018.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small molecule that is being developed as a potential disease-modifying therapy for all patients affected by DMD, regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a protein that is activated in DMD and drives inflammation and fibrosis, muscle degeneration and suppresses muscle regeneration. Edasalonexent continues to be dosed in the open-label extension of the MoveDMD Phase 2 clinical trial and Catabasis plans to initiate a single global Phase 3 trial to evaluate the efficacy and safety of edasalonexent for registration purposes in the first half of 2018. The FDA has granted orphan drug, fast track and rare pediatric disease designations and the European Commission has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. For a summary of clinical results reported to-date, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our SMART (Safely Metabolized And Rationally Targeted) Linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART LinkerSM platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more information on the Company’s drug discovery platform and pipeline of drug candidates, please visit www.catabasis.com.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about future clinical trial plans including, among other things, statements about the Company’s plans to commence a single global Phase 3 trial in DMD in the first half of 2018 to evaluate the efficacy and safety of edasalonexent for registration purposes, the Company’s plans to report top-line results from this trial in 2020, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates, including the final trial design of the Company’s planned Phase 3 trial in DMD; availability and timing of results from preclinical studies and clinical trials, including the availability of top-line results from the Company’s planned Phase 3 trial in DMD in 2020; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the Company’s ability to obtain financing on acceptable terms and in a timely manner to fund the Company’s planned Phase 3 trial of edasalonexent in DMD for registration purposes; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s product candidates; and general economic and market conditions and other factors discussed in the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2017, which is on file with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.
Zion Oil & Gas, Inc. (NASDAQ: ZN) announces that during the current open hole wireline logging and subsequent reaming (cleaning the well bore) operations, Zion encountered free-flowing hydrocarbons while circulating drilling mud.
Zion’s President and Chief Operations Officer, Dustin Guinn, provided further understanding of recent events stating, “We were cautiously optimistic given the amount of gas that accumulated in the well after returning from Shabbat after calling total depth (TD) at 5,026 meters (~16,500 feet). After making our first of three open hole logging runs, we decided to ream to bottom to clean the hole out in anticipation of our second logging run. After circulating the well, we experienced a continued and significant increase in gas followed by clear evidence of oil in our circulated mud from the bottom of the well. This is obviously very exciting news and as a result, we have decided to continue to drill up to another 70 meters (~230 feet). We expect that to take a couple of days, and barring any operational difficulties, we will continue with our open hole logs immediately thereafter.”
Zion’s CEO, Victor G. Carrillo, added, “I am ecstatic to see clear evidence of hydrocarbons (oil and gas) in the deeper portion of our Megiddo-Jezreel #1 well – a project that we have been working on for years. However, at this time we cannot comment on the commerciality or ability to successfully produce the well. We ask that our shareholders continue to pray for safe and successful drilling, logging, and testing operations, and for God’s wisdom for management as we make key decisions in the following days and weeks. Please be patient. We will provide further updates after we have adequate time to properly evaluate the logs and finalize our well testing program following the recent events.”
“For You are great, and do wondrous things; You alone are God.” Psalm 86:10
“In His hand are the deep places of the earth …” Psalm 95:1-7
FORWARD-LOOKING STATEMENTS: Statements in this communication that are not historical fact, including statements regarding Zion’s planned operations, anticipated attributes of geological strata being drilled, the presence or recoverability of hydrocarbons, operational risks in testing and well completion, timing and potential results thereof and plans contingent thereon are forward-looking statements as defined in the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions that are subject to significant known and unknown risks, uncertainties and other unpredictable factors, many of which are described in Zion’s periodic reports filed with the SEC and are beyond Zion’s control. These risks could cause Zion’s actual performance to differ materially from the results predicted by these forward-looking statements. Zion can give no assurance that the expectations reflected in these statements will prove to be correct and assumes no responsibility to update these statements.
Contact Info:
Zion Oil & Gas, Inc. (NASDAQ: ZN)
12655 North Central Expressway, Suite 1000, Dallas, TX 75243
Andrew Summey
Telephone: 888-891-9466
Email: andrew.summey@zionoil.com
www.zionoil.com
VANCOUVER, British Columbia, Feb. 13, 2018 — via NetworkWire – Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), a biopharmaceutical company engaged in the development and commercialization of cannabinoid-based therapeutics using innovative drug formulation and delivery platform technologies, wishes to to address the recent decline in its share price.
There has been no material change to Pivot’s business plan that would justify the market decline. Pivot continues to successfully execute on its business strategy. Product development is advancing as planned and discussions are ongoing with potential acquisition or joint venture partners. We continue to aim for product sales commencing with the change in regulations anticipated to take effect in Canada in July 2018. Our recent press release clearly highlighted several key milestones achieved by Pivot and its world-class scientific collaborators.
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to a Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com
Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. As a result of the foregoing, actual results could differ materially from those contemplated by the forward-looking statements as a result of the foregoing factors and certain other factors, such as the failure to meet the conditions imposed by the regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
February 13, 2018
NetworkNewsWire Editorial Coverage: As the legalization of medical marijuana spreads, the appetite for investment in the cannabis biotech sector keeps growing. This is the largest sector of the legal cannabis market, already a multi-billion-dollar market. Researchers continue to uncover new ways that cannabinoids, chemical compounds found in cannabis, can be used as medicine. Earth Science Tech (ETST) (ETST Profile) offers full-spectrum, high-grade hemp cannabidiol (CBD) oil, and is researching cutting-edge CBD products through its subsidiary Cannabis Therapeutics, Inc. (CTI). The creator of the first cannabis-based prescription medicine, GW Pharma (GWPH) is working on new drugs to tackle epilepsy, while Medical Marijuana, Inc. (MJNA) provides a range of CBD oils with medical and nutritional benefits to customers across North and South America. CV Science, Inc. (CVSI) utilizes separate drug development and consumer product divisions to create and market a diverse range of CBD products to a variety of markets, and Cannabis Science, Inc. (CBIS) is developing formulation-based drugs based on cannabinoid science.
A Thriving New Sector
The legal cannabis sector is booming. According to the Brightfield Group, it is already worth over $7 billion and expected to grow to $31 billion by 2021. Within that market, CBD products are a significant sector, expected to hit $1 billion in the next few years. Even the more conservative U.S. states are overcoming their objections and opening up to CBD production and sales, as legislators seek to resolve legal ambiguities in favor of patients.
While the emergence of a recreational cannabis market in regions such as Canada and California is exciting news for the cannabis industry, the industry’s financial security rests on medical products. The loosening of laws makes research easier, as does the growing experience of medical cannabis companies. CBD is a particularly rich source of therapeutics with the potential to be utilized against a wide range of ailments. Researchers are exploring its potential to tackle such enduring problems as epilepsy, anxiety, depression and breast cancer.
Innovating in Cannabidiol
Biotechnology company Earth Science Tech (ETST) has diverse interests within the cannabis market. Its subsidiaries cover diagnostics and vaccines, recreational cannabis and CBD products. In that last area, it’s leading the way in researching and marketing a wide variety of CBD-based treatments through innovative partnerships and collaborative research.
Earth Science Tech’s CBD work is carried out through its subsidiary Cannabis Therapeutics, Inc. (CTI). The company’s CBD oil is 100 percent natural and organic, catering to the environmental concerns common among cannabis users. It is made using a CO2 liquid extraction process that results in a full-spectrum, high-grade hemp CBD oil that has the highest purity and quality on the market.
To keep it in the lead of the CBD market, Earth Science Tech has created partnerships with other research bodies to produce cutting-edge treatments. It is working with the University of Central Oklahoma and DV Biologics Laboratory on research and development projects to enhance the healthcare benefits of its CBD oil. This has positioned the company to take a leadership role in the development of cannabinoid-based pharmaceutical and nutraceutical products. The company holds a provisional application patent for a CBD product for treating breast and ovarian cancers, taking CBD treatments in bold new directions.
Reaching New Market Sectors
Cannabis Therapeutics currently has two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products in development. These are being made to treat a range of ailments including anxiety, depression and fatty liver disease.
One major focus is integrating the CBD molecule with existing generic drug molecules to create more efficient medications that have fewer side effects than the more common approaches. The company is therefore engaged not only in making cannabinoids useful and available to a wider range of patients, but in creating a better experience for existing patients.
Other research into medical cannabinoids by Earth Science Tech could counter conservative fears about the impact of medical cannabis on the illegal drug market. In November 2017, the company began human trials on a new CBD formula designed to decrease cravings and the negative effects of withdrawal in opioid addicts. Based on industrial hemp CBD mixed with a natural ingredient that increases dopamine levels, it could be used to counter the opioid epidemic plaguing many countries. By turning medical CBD into a weapon in the fight against addiction, it will reposition cannabis in the public discourse on drug use. This has the potential to counter resistance to the expansion of the medical cannabis market.
Raising the Brand Profile
Earth Science Tech has a wide variety of products, giving it good reach within the CBD market. Its CBD treatments are available as vitamins, minerals, herbs, botanicals, personal care products, homeopathic treatments and foods. Other products come in forms including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Available at retail stores across the United States and online, they have a combination of physical shelf presence and online visibility to raise their profile with consumers.
The company is currently rebranding its CBD products (http://nnw.fm/s6pC1), using market research to drive improved sales. The chief marketing officer commented, “We did a lot of market research to see what the best angle to truly stand out in the growing CBD industry is through our accounts, representative feedback, and external brand analysis. I feel that marketing, ‘High Grade Full Spectrum Cannabinoids’ will help ETST truly stand out. Soon, the market will be able to see that ETST is a true full spectrum CBD brand, especially with the cannabinoid complex listing under the supplement facts.”
As a result of this research, previous marketing of the company’s products as, “High Grade Hemp CBD Oil” is being replaced with “High Grade Full Spectrum Cannabinoids.” Branding will also include the addition of “Cannabinoid Complex”. The supplement facts will show the breakdown of the full spectrum of CBD oils being used, including CBD, CBG and CBDA.
Box packaging has been designed to incorporate these changes and a modern, edgy look while maintaining the clean design associated with medicinal products.
Better Distribution
Taking these revamped products into American stores (http://nnw.fm/pd51A) is the first major distributor for Earth Science Tech’s products — Mr. Checkout.
Mr. Checkout, as featured on ABC’s Shark Tank, is a national group of independent distributors, full-line grocery distributors and convenience stores. It represents products in over 60 major U.S. retail outlets with approximately 55,000 stores. Mr. Checkout’s accounts include Walgreens, CVS, Walmart, Wholefoods Market and Target. This distribution deal provides a direct route for Earth Science Tech’s products onto the shelves of powerful retail stores with a large consumer base.
Earth Science Tech has 10 active representatives opening and managing accounts across the United States. These representatives have been very successful with health food stores and clinics. The distribution agreement with Mr. Checkout will take the company’s products beyond this market, into major retailers and stores, substantially expanding the company’s reach.
Gabriel Aviles, Earth Science Tech’s chief sales officer and director, said about the deal, “I feel that we have finally put together a solid productive team of representatives that we needed to continue expanding our presence in health shops and clinics. Now, with Mr. Checkout, we will be able to take our presence and sales to the next level, entering larger retailers and many stores. 2018 looks to be starting off very strong with our new product revamp, marketing and education strategy, and sales channel.”
Growing Consumer Choice
The growth of the medical cannabis sector means that Earth Science Tech’s products sit among a wide range of brands on the ever-growing shelves of CBD oils.
British cannabis company GW Pharma (GWPH) has developed Sativex, the first prescription medicine derived from the marijuana plant. This has been approved for Multiple Sclerosis spasticity and neuropathic pain in 29 countries. The company is currently seeking FDA approval for Epidiolex, a CBD-based treatment for epilepsy, after the drug was found to be effective in clinical trials.
Medical Marijuana (MJNA), one of the pioneers of the cannabis sector in North and South America, offers its flagship product Real Scientific Hemp Oil (RSHO) in three varieties. RSHO was the first legal CBD oil in both Brazil and Mexico, and the company was the first publicly traded cannabis business in the United States. A global leader in the medical marijuana industry, this forward-looking company is also exploring the nutritional potential of hemp.
CV Science (CVSI) is divided into two segments: a drug development division focused on creating and commercializing novel CBD-based therapeutics, and a consumer product division that manufactures, markets and sells plant-based CBD products. It is tapping into a wide range of market sectors through products such as its Purified Liquids products for vaping. Its PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry.
Recognizing the long history of cannabinoids for health purposes and supporting peer-reviewed scientific journals, Cannabis Science (CBIS) is focused on the discovery and development of novel cannabinoid-based therapies as treatment options for unmet medical needs. Its immediate focus is on the treatment of cancer.
Cannabinoids are an increasingly important part of the growing cannabis sector. Companies that can combine strong branding, customer outreach and innovative products are likely to see great growth as the market expands by billions each year. And as research finds new therapeutic uses for these chemicals, they are set to improve the lives of thousands of patients.
For more information on Earth Science Tech, visit Earth Science Tech (ETST)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Company enters into license agreement with Strategic Science & Technologies, LLC to develop Topical Sildenafil, now in Phase 2 clinical studies
SAN DIEGO, Feb. 12, 2018 — Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has entered into an agreement to license SST-6007 (5% Topical Sildenafil Citrate Cream), a potential treatment for Female Sexual Arousal Disorder (“FSAD”), from Strategic Science & Technologies, LLC (“SST”). FSAD is characterized primarily by an inability to attain or maintain sufficient physical sexual arousal that causes distress or interpersonal difficulty. SST-6007 incorporates sildenafil, the same active ingredient in Viagra®, in a proprietary cream formulation that is specifically designed to locally increase blood flow to the vulvar-vaginal tissue in women, leading to a potential improvement in genital arousal response and overall sexual experience. If approved, Daré believes SST-6007 would be the first FDA approved treatment for FSAD.
SST-6007 is the second product in Daré’s growing portfolio of novel therapeutic candidates that address unmet needs in women’s reproductive and sexual health. Daré’s first product candidate undergoing clinical development in the United States is Ovaprene™, a non-hormonal contraceptive ring with the potential to be the first non-hormonal product to provide monthly contraceptive protection.
“We look forward to working closely with SST to bring SST-6007 to the market for women, leveraging SST’s deep knowledge of FSAD and our experience developing innovative women’s health products and readying them for U.S. commercialization. Driven by a mission to identify unmet needs in women’s health and mining the globe for unique assets that would serve these needs, we are confident that SST-6007 has the potential to significantly impact women with Female Sexual Arousal Disorder, an area that has long been studied but for which there are currently no FDA approved treatments,” said Sabrina Martucci Johnson, President and CEO, Daré Bioscience.
“While increased attention has been focused on female sexual dysfunctions over the past several years, no pharmacologic options have yet been FDA approved for Female Sexual Arousal Disorder (FSAD), a condition which significantly compromises a woman’s ability to have a pleasurable sexual experience,” commented Dr. Sheryl Kingsberg, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center. “I am very excited about the potential for Topical Sildenafil to address this critical unmet need in women’s sexual health. Leveraging the known therapeutic benefit of Viagra® to stimulate increased blood flow to the genital tissue, Topical Sildenafil may offer these women a safe, effective and ‘on demand’ solution to difficulties with sexual arousal allowing for a more intense and enjoyable sexual experience.”
In a Phase 2 study, SST-6007 demonstrated an increase in blood flow to the vaginal tissue in both pre- and postmenopausal women with FSAD. Daré plans to pursue the 505(b)(2) regulatory pathway for SST-6007 in the U.S. and leverage the existing data and established safety profile of the Viagra® brand. Daré anticipates commencing a Phase 2b clinical trial in the second half of 2018.
With the potential introduction of SST-6007 as the first FDA approved product for FSAD, Daré is poised to create a new market category within the female sexual dysfunction space. A report by Visiongain forecasts that the world market for both male and female sexual dysfunction drugs will reach $7.7 billion in 2019.
About Strategic Science & Technologies, LLC
Strategic Science & Technologies, LLC (SST) is a clinical-stage biotechnology company with an innovative topical drug delivery technology. The company’s patented delivery technology provides targeted local delivery of known drugs at therapeutic levels. SST’s product portfolio includes Topical Ibuprofen and Topical Sildenafil, both in clinical development. SST is headquartered in Cambridge, MA and remains privately funded by its original investors. For more information please visit www.strategicscience.com.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. The company is driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health and fertility. Daré’s lead product candidate, Ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies. The company is headquartered in San Diego. For more information please visit www.darebioscience.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995 regarding matters that are not historical facts, including statements relating to Daré’s expectations regarding the anticipated market demands for its products, the safety and effectiveness of its products, market acceptance of Daré’s products and the qualifications and expertise of Daré’s management team. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation and completion of clinical trials; availability and timing of data from ongoing and future clinical trials and the results of such trials; whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals; claims of infringement and other risks relating to Daré’s owned and licensed intellectual property rights, and other factors discussed in the “Risk Factors” section of Daré’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2017. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Daré’s reports to the Securities and Exchange Commission, including Daré’s reports on Forms 10-Q, 8-K and 10-K. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. Daré specifically disclaims any obligation to update any forward-looking statements included in this press release.
Media Contact:
Amanda Guisbond
Vice President
Canale Communications
Amanda@canalecomm.com
781-405-8775
New York, New York–(February 12, 2018) – NetworkNewsAudio announces the Audio Press Release (APR) titled “Hemp Provides Investors Access to Larger Cannabidiol Market,” featuring ChineseInvestors.com (CIIX).
To hear the NetworkNewsAudio version, visit: LINK
To read the original editorial, visit: LINK
The company’s hemp-based health products are available in the United States and Canada. CEO Warren Wang aims to double the company’s revenue and expand the business in 2018, with growth in North America as well as China. One of the tools to achieve this is a Yelp-style app for CBD customers. Approved for download by the Apple App Store, it is the world’s first Chinese-language mobile cannabis navigation application. The app carries an easily searchable database of marijuana dispensaries and cannabis strains. Customers can use the platform to review and discuss cannabis products, allowing them to find the best recommendations and nearby locations for medical and recreational cannabis. This will broaden the company’s reach and raise its profile in the growing number of states where marijuana is legally accessible.
CIIX is committed to further research into the use of hemp oil and other CBD products. The company in investing in research and design enterprises with the goal of developing CBD drugs to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this type in China is two to four years, meaning that the company will be able to bring products to market far more quickly than in the United States. If this research pays off, then the company will not only be providing new uses for products in a growth sector of the economy, it will also be in position to launch them in the largest customer market in the world.
About ChineseInvestors.com
Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products. For more information visit www.ChineseInvestors.com.
About NetworkNewsAudio
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit: www.NetworkNewsAudio.com
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
VANCOUVER, British Columbia, Feb. 12, 2018 — Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), a biopharmaceutical company engaged in the development and commercialization of cannabinoid-based therapeutics using innovative drug formulation and delivery platform technologies, is pleased to provide its shareholders with the following Corporate Update.
Pivot has had a very active start to 2018 as the management team continues to build a “differentiated” company in the cannabis sector, focusing on improving the cannabis consumer experience with scientifically derived products. Pivot’s world-class patent portfolio and industry leading pipeline, supplemented by experienced scientists and developers, will allow the Company to flourish as it continues to produce effective, stable and dosable products for health-conscious consumers.
Current products available to consumers are either smoked or are unable to deliver meaningful amounts of cannabis into the body. Pivot believes that only companies that have pharmaceutical-grade products supported by strong clinical or medical data will meet the consistency and desired health effects demanded not only by consumers, but also by regulatory authorities such as Health Canada.
Highlights:
- Acquisition of ERS Holdings, LLC (“ERS”) and Ready-to-Infuse-Cannabis Patents: Pivot has completed the Definitive Agreement and closing is scheduled on or before February 28, 2018. Monetization of the patented Ready-To-Infuse-Cannabis Oil-to-Powder technology (“RTIC”) is a top priority for Pivot. A recent report states that cannabis sales have surpassed liquor store sales in Aspen, Colorado for the first time since legal adult-use sales began in 2014. Forbes, citing a study by Cannabiz Consumer Group, states that “the beer industry could lose more than $2 billion in retail sales to legal marijuana”. With the ERS acquisition, Pivot is well positioned to participate in the lucrative global cannabis-infused-beverage market and has already identified potential co-development partners in the alcohol beverage industry.
- Acquisition of Thrudermic, LLC: Pivot previously announced a Binding Letter of Intent to acquire worldwide rights to Thrudermic’s patented Transdermal Nanotechnology for the development and commercialization of transdermal cannabinoids. The Company has now exercised its right to acquire 100% of Thrudermic, LLC, with closing scheduled on or before February 28, 2018. Pivot’s management has been very impressed with the capabilities of Dr. Leonid Lurya and Dr. Joseph Borovsky and are excited to have them lead Pivot’s product development team. The ability to develop products in Israel using Dr. Lurya’s patents provides the Company with access to CBD/THC licensed labs, ensuring that Pivot will have several products ready for sale in countries where regulations permit.
- Product Development Update:a. Micelle 1% CBD oral solution is ready for market. Formulated using Solmic GmbH’s patented solubilisation technology, CBD is rendered water-soluble and results in higher bioavailability and stability.
b. Pivot Topical CBD: Dr. Leonid Lurya, working in partnership with Solubest Ltd. (located in the Weizmann Science Park in Israel) has now completed formulation of this product. The semi-solid cream is being evaluated for stability at this time.
c. Pivot’s development team has initiated development of Thrudermic transdermal nanotechnology for a systemic CBD product.
- Growing IP Portfolio: Pivot continues to evaluate drug delivery technologies that can assist with the delivery of cannabinoids for human and veterinary use. The Company has filed three additional provisional patents for using nanotechnology delivery of cannabis from various routes of administration:a. Transdermal nanotechnology delivery system of cannabis using patches and creams;
b. Mucus topical cannabis delivery system through buccal, nasal, vaginal and anal areas of entry using a gel, suppository or mouthwash; and
c. Inhalation delivery system of cannabis for topical or systemic use.
In addition, the Company is expecting positive feedback from the United States Patent and Trademark Office regarding continuation patents using RTIC technology which will allow for novel formulations of cannabis with various health and wellness products such as over-the-counter sleep aids, and cough and cold medication among others. This is in addition to capsules, K-Cups, stick packs, and other infused beverages such as vitality drinks.
- Standstill Agreement: The previously announced Standstill Agreement has been mutually terminated and as a consequence, other broader opportunities have arisen. Pivot will favor those options that allow it to control all aspects of the cannabis process, from raw materials to formulation, resulting in the highest quality bio cannabis products. These options may include the acquisition of, or Joint Venture with, a Licensed Producer and/or Licensed Dealer. Pivot’s management will select the transaction that helps create a long-term, sustainable company and provides the greatest value for shareholders.
- Out-licensing of Pivot’s IP: Pivot continues to receive inquiries from companies interested in licensing pipeline products and/or patents. This interest confirms the validity of Pivot’s IP strategy. As the cannabis space is emerging, only those products with adequate IP protection will provide a competitive advantage, allow trademarking and branding, and protect innovation.
- European Distribution Partner: Pivot has selected and advanced discussions with an established European-based natural health company to market and distribute products in the EU. A report by Prohibition Partners mentions that “the European medical cannabis market will be valued at almost €50b once all markets have implemented legislation and market infrastructure. This does not include revenue that will be generated from the additional secondary market and ancillary services. EIHA, Nova-Institute and HempConsult estimate that the European market for CBD as a pharmaceutical product is already worth €2b alone.”
Dr. Patrick Frankham, Pivot’s CEO states “I am extremely proud of the entire Pivot team as we continue to execute our business plan. We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes. We continue to believe that sustainable cannabis companies will have pipelines of products to meet the needs of consumers seeking wellness and healthy lifestyles.”
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to a Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com
Cautionary Statement
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot or Pivot Green Stream, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. As a result of the foregoing, actual results could differ materially from those contemplated by the forward-looking statements as a result of the foregoing factors and certain other factors, such as the failure to meet the conditions imposed by the regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
Contact:
Pivot Pharmaceuticals Inc.
Patrick Frankham, PhD, MBA
Chief Executive Officer
Tel: (514) 943-1899
Email: Info@PivotPharma.com
BETHESDA, Md., Feb. 12, 2018
India Globalization Capital, Inc. (NYSE-MKT:IGC) announced today that Ram Mukunda will be a speaker at the upcoming CEO Healthcare Symposium in New York on February 12 and February 13, 2018. His presentation will include commentary on the Company’s efforts in developing and commercializing cannabis–based pharmaceuticals including Hyalolex for Alzheimer’s disease.
2018 Key Objectives
“We are preparing the groundwork necessary to prepare Hyalolex, our lead product formulation for Alzheimer’s ready for Phase 2-B human trials. Independent of this, we expect to make the product available through medical dispensaries in select states of the U.S. In addition, we are working on addressing issues specific to the medical cannabis industry such as transactional difficulties, inadequate product labeling, product identification assurance (PIA) and product origin assurance (POA), using distributed ledgers inherent in blockchain technology. We look forward to an exciting 2018 and I wish to thank YJP for the opportunity to speak at their CEO Healthcare Symposium alongside prestigious leaders and innovators in the healthcare industry,” commented Ram Mukunda, CEO.
About the CEO Healthcare Symposium
This event, sponsored by YJP (www.yjp.org) will feature speakers from the hospital, insurance, biotech, pharma, medical device, medtech, senior living, and home care sectors and will bring together top executives from across the healthcare spectrum to discuss the current and future market trends that we are seeing in the industry.
About Alzheimer’s disease
Alzheimer’s Disease (AD) is a form of dementia. It is known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion. AD currently affects more than 5.3 million Americans and over 65% of AD patients are women. Over the next 20 years, the number of those afflicted with the disease is expected to double. The forecast is staggering, considering that to date, no effective cure has been found.
About IGC
IGC has two lines of business, a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry that address transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The company is based in Maryland, USA.
For more information please visit www.igcpharma.com
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.
Contact:
Claudia Grimaldi
301-983-0998
January 30, 2018
- Standard Lithium works to reduce political, permitting and technology risks
- Standard Lithium is expanding facilities into southern Arkansas
- Innovative low-risk opportunities being sought to meet the increasing demand for lithium
Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) actively seeks to reduce political, permitting and technology risks, all while positioning itself as a leader in the production of lithium. The company works to eliminate exploration and development risks by focusing on existing brine fields and partnering with U.S. chemical processing companies. By focusing on U.S.-based assets, Standard reduces political and geographical risks, working within jurisdictions that already understand how to permit and approve brine extraction and processing at large industrial scales. Whenever possible, Standard partners with companies holding existing permits and licenses in favorable jurisdictions. Technology risks are decreased by leveraging existing industrial processes and extraction technologies, partnering with world class chemical processing engineers and using leading scientific and engineering advisory teams.
A network of brine production wells in southern Arkansas provides access to the Smackover Formation. In a statement made by Standard Lithium’s Chief Executive Officer, Robert Mintak, there is talk of building a Pilot Plant “fed by a network of brine production wells in southern Arkansas that access underground brine from the Smackover Formation and transport it via an extensive system of pipelines and related infrastructure.”
In the last 80 years, the Smackover Formation has produced billions of barrels of brines. This opportunity will give the company access to tail brines for the testing of viable lithium extraction and aligns fully with Standard Lithium’s goal of creating efficient processing techniques to produce battery-grade lithium products from otherwise overlooked brine resources.
With the demand for lithium set to increase by more than 300 percent in the next eight years, the company is looking for innovative low-risk opportunities to meet the need. In the Mojave Desert of California, it is using the region’s record-high evaporation rates to its advantage. Standard has installed six new separate evaporation ponds at its Bristol Dry Lake property for extensive brine extraction and processing. The company’s project area in California covers over 45,000 acres, and its recent entry into an option agreement with TETRA Technologies Inc. will provide access to 33,000 acres of brine leases in southern Arkansas.
The world’s demand for lithium is on the uptick with the ever-increasing interest in electric vehicles, smartphones, laptops and other battery-operated technologies. Standard Lithium is positioning itself to be a leader in the industry. In 2017, its stock returned 348 percent to investors, and the company has a current market cap of around C$136 million.
For more information, visit the company’s website at www.StandardLithium.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NEW YORK, NY / February 9, 2018 / WallStreet Research™ (WSR), a top-ranked independent research firm with a history spanning over three decades, today announced that the firm has updated corporate profile coverage on Pressure BioSciences, Inc. (OTCQB: PBIO). WallStreet Research™ is ranked Number One on the Google, Yahoo, and Bing search engines in both small and microcap research with a global following. An updated analyst Corporate Profile Report, together with additional information about WallStreet Research™, is available at the www.WallStreetResearch.org website.
The updated WSR Corporate Profile highlights the last half of 2017 accomplishments and the growth plans, which the Company (PBI) has implemented for 2018 and beyond.
One of the major accomplishments last year was the redesign and enhancement of their products and technology. Additionally, PBI has significantly expanded their sales and marketing capabilities. Earlier in 2017, PBI operated with just two domestic sales directors, yet it was still able to grow the company on such limited staffing. Recently, PBI has hired four more domestic sales directors, now operating with six sales positions, which should enable it to grow significantly in 2018. PBIO also has increased its distribution network by expanding the marketable territories for I&L Biosystems, exclusive agent for Western Europe. And adding Vita, Inc as exclusive distributor in Japan. The company already works with Powertech, exclusive agent for China.
PBI recently completed the acquisition of all assets of BaroFold, Inc. Among the assets acquired were all patents, equipment, and intellectual property relating to BaroFold’s PreEMT™ high-pressure protein refolding and disaggregation technology. This patented technology employs high pressure for refolding of recombinant proteins into their native structures for desired pharmacological activity. With the Company’s proven ability to develop and commercialize effective high-pressure technology solutions and grow its worldwide customer base, and with its recent expansion of its sales force, PBIO should increase the reach of BaroFold’s technologies into many new research laboratories and biopharmaceutical companies, increasing sales. PBI also has increased its efforts working with distributors to market its products now in the USA, China, Europe and the Pacific Rim.
2017 was a continued growth year for PBI. The Company reported that total revenue increased 20.7% to $646,061 for Q3 2017 as compared to $535,334 for Q3 2016. Third quarter 2017 products and services revenue increased by 21%, consumable sales increased by 158% and grant revenue increased by 23%. For the 9 months ended Sept 30, PBI reported total revenue growth of 11.6% to $1.74 million, and posted an operating loss of $3.3 million.
Mr. Alan Stone, Managing Director of WallStreet Research™, added, “WSR has followed Pressure BioSciences for some time now and the team is impressed with the Company’s continued ability to increase sales to record levels each quarter, cut costs, and position itself for long term growth. With the addition of more sales, together with plans in place for strengthening the balance sheet, we believe the Company is well positioned for significant growth during the upcoming quarters of 2018 and beyond. Additionally, we believe that the core value of the Company’s products and technologies are not being adequately valued in the marketplace.”
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Information on PBIO can be found at www.pressurebiosciences.com.
About WallStreet Research™
WallStreet Research™ (“WSR”) is a prominent research boutique led by Mr. Alan Stone, Managing Director of Alan Stone & Company, LLC (ASC). The firm specializes in the microcap and small cap investment arena, looking for emerging growth companies with strong management, unique or proprietary technology, significant market potential, financial strength, and outstanding long-term earnings growth possibilities. Mr. Stone was formerly a securities analyst and assistant portfolio manager at Merrill Lynch Asset Management, an investment analyst at Prudential Financial’s Capital Markets Group, and an investment banker with Ladenburg Thalmann & Company. The firm has offices in Los Angeles, CA, Palm Beach, FL, and New York City, NY, and is well known for discovering undervalued companies and bringing them to the attention of the investment community. ASC/WSR also arranges road shows for its publicly traded clients, before the investment community in New York City, California and Florida. Information on WallStreet Research™ can be found at www.WallStreetResearch.org.
Disclaimer
The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investments in securities mentioned here contain inherent and significant risks, and are suitable only for speculative oriented investors. Any investments should only be made after consulting an investment professional. The featured company will pay a fee of $3,500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relations’ services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.
Contact / Source:
WallStreet Research™
Alan Stone, 310-444-3940
astone@alanstone.com
Barbara Blake, 415-419-4239
bjblake1229@att.net
www.WallStreetResearch.org
www.SouthFloridaInvestmentForum.com
www.SouthernCaliforniaInvestmentForum.com
www.SmallCapConference.org
Pressure BioSciences, Inc.
Richard T. Schumacher, CEO
14 Norfolk Ave. South Easton MA, 02375
Phone: 508-230-1828
www.pressurebiosciences.com
February 1, 2018
- Transdermal cannabis-based therapy promises greater absorption, less side effects
- Global medical marijuana market projected to reach $55.8 billion U.S. by 2025
- Novel CBD delivery method targets array of unmet healthcare needs
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.
Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.
Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.
Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).
The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.
Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.
For more information, visit the company’s website at www.PivotPharma.com
More from CannabisNewsWire
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
February 8, 2018
NetworkNewsWire Editorial Coverage: With the rapid growth of the legal American cannabis market, other cannabidiol (CBD)-based products are often overlooked. In particular, hemp has the opportunity to reach medical and nutritional customers that cannabis can’t, and ChineseInvestors.com (CIIX) (CIIX Profile) is tapping into that market. With the potential to provide similar benefits without the same restrictions, hemp products can be sold in markets such as China, where cannabis remains illegal. It’s a part of the market that CBD industry leaders such as Freedom Leaf, Inc. (FRLF) are also catering to, with marketing and media products for hemp companies. Medical Marijuana, Inc. (MJNA), America’s first publicly traded cannabis company, is carrying its CBD business beyond the United States and across the Americas, while CV Sciences, Inc. (CVSI) combines scientific research with a consumer products division to bring innovative CBD products to the market. At the farming end of the supply chain, Terra Tech Corp. (TRTC) provides advanced agricultural solutions and new, better strains of cannabis for a growing market.
The Growing Cannabidiol Market
The market for legal marijuana is growing at an ever-accelerating rate. Recent research by Arcview Market Research and BDS Analytics indicates that sales in North America reached almost $10 billion in 2017 and are expected to reach $24.5 billion by 2021 as more markets are created for both medical and recreational use. But this is still a sector threatened by great uncertainties and limitations. With no legal cannabis market in many parts of the globe, and with the current U.S. administration dominated by anti-marijuana conservatives, legal marijuana represents the troubled part of a larger CBD market.
For companies looking to that wider market, hemp offers a growing option for the CBD industry, one unfettered by many of the restrictions limiting marijuana. A report by the Brightfield Group shows that hemp is likely to become a billion-dollar market in the next three years. Used like cannabis in medicinal and nutritional products, it benefits from a high portion of online purchases – nearly two-thirds of hemp sales happen online.
Hemp also has the potential to reach larger international markets. The American-led war on drugs has encouraged an international climate that’s hostile to cannabis sales, but in which hemp products mostly remain legal.
Bringing Cannabidiol Products to China
One of the companies best set to make the most of this opportunity is ChineseInvestors (CIIX).
Founded in 1999, ChineseInvestors.com is a leading financial information website for Chinese-speaking investors in both the United States and China. Through its website, the company offers a range of investor information and services, including real-time market commentary, analysis and educational products. It also provides support services for companies looking to get into the Chinese market, including consulting for companies considering going public, advertising services and public relations-related support. With information in both English and Chinese language character sets, it provides an accessible presentation for investors looking at China both from the inside and the outside.
This is built around the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. In this way, CIIX helps investors make informed investment decisions and helps them meet their individualized financial goals. This includes a division committed to cryptocurrencies (http://nnw.fm/3pwZV), producing daily videos to inform Chinese investors about this ever-growing and unregulated sector of the Chinese economy.
Its position at the intersection of American and Chinese markets has put CIIX in a perfect position to explore the wider cannabidiol market. Marijuana use is illegal in China, but CBD oils, including hemp-based CBDs, are legal. CIIX is committed to developing and distributing hemp-based products in hopes of helping people improve their overall health, targeting epilepsy, Alzheimer’s disease, cirrhosis of the liver and various other health conditions. With nearly 10 million epilepsy patients in China, products that can help these customers have the potential to become big sellers in a growing market.
In December 2016, CIIX reached a wholesale agreement with a CBD health brand. Off the back of this, it launched its new subsidiary ChineseCBDoil.com. This website went live on Jan. 31, 2017, providing the world’s first Chinese language online store for CBD health products. It provides a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates available to Chinese-speaking customers worldwide.
Though the company has emphasized the health benefits of CBD products, it is also leveraging its financial and marketing expertise to sell hemp-infused skin care products in China.
Sales thus far have been so successful that the company is spinning off its subsidiary — CBD Biotechnology and ChineseHempOil.com, Inc. — with the intention of listing the new company’s common stock on the OTCQB (http://nnw.fm/Mxi3e). The site offers a variety of hemp oil products, including OptHemp Ultra Premium oil, peppermint-flavored hemp oil in softgels and gummies, and the Gold Plus line of premium hemp oil.
CIIX CEO Warren Wang expressed his confidence in this new development, stating in a press release, “We are excited to announce our intention to spin off CBD Biotechnology and ChineseHempOil.com, Inc. as we believe the existing business lines and the new acquisitions in China, secured by CEO Summer Yun, will allow these entities to continue to grow in their respective markets, while bringing new value to the Company’s existing shareholders.”
Growth and Challenges in America
The company’s hemp-based health products are available in the United States and Canada. Wang aims to double the company’s revenue and expand the business in 2018, with growth in North America as well as China. One of the tools to achieve this is a Yelp-style app for CBD customers. Approved for download by the Apple App Store, it is the world’s first Chinese-language mobile cannabis navigation application. The app carries an easily searchable database of marijuana dispensaries and cannabis strains. Customers can use the platform to review and discuss cannabis products, allowing them to find the best recommendations and nearby locations for medical and recreational cannabis. This will broaden the company’s reach and raise its profile in the growing number of states where marijuana is legally accessible.
CIIX is committed to further research into the use of hemp oil and other CBD products. The company in investing in research and design enterprises with the goal of developing CBD drugs to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this type in China is two to four years, meaning that the company will be able to bring products to market far more quickly than in the United States. If this research pays off, then the company will not only be providing new uses for products in a growth sector of the economy, it will also be in position to launch them in the largest customer market in the world.
Because CBD remains classified as a Schedule 1 drug under the Controlled Substance Act administered in the United States by the Drug Enforcement Administration, hemp sales are regarded as illegal by the federal government despite the growing number of states legalizing it under their authority. Schedule 1 drugs are identified as substances with a high potential for abuse, no currently accepted medical use in the United States and a lack of safety protocols under medical supervision (http://nnw.fm/Nm4CO). This prohibition is being challenged in court, and that challenge now has the backing of a cross-party group of Congress members. The Congressional group’s arguments to the court state that the DEA’s ruling on CBD was an “abuse of DEA’s administrative procedure and rulemaking authority” and contrary to the definition of hemp set down by legislators in the 2014 Farm Bill (http://nnw.fm/Y2EPp). With such strong political support, the hemp industry is optimistic that this case will result in clarity and a lifting of the restrictions to permit easier expansion of CBD-based sales for companies such as CIIX.
The Cannabis Industry Connection
The deep connection between hemp production and the wider cannabis industry is shown by the work of companies such as Freedom Leaf (FRLF). A leading media producer and distributor in the cannabis and hemp industries, Freedom Leaf is a trusted source of information in the sector. The company is involved in mergers and acquisitions in the marijuana industry and has a portfolio of news, print and digital multi-media verticals, websites and web advertising, establishing it as a media outlet and discussion forum for a growing group of industries. It also provides services in branding, licensing and marketing these products, positioning it to make the most of fast growth in this sector.
One of the great pioneers of the cannabis sector in both North and South America, Medical Marijuana, Inc. (MJNA) is also involved in hemp. The first publicly traded cannabis company in the United States, the company also is situated in Brazil and Puerto Rico. This forward-looking company is exploring the medical and nutritional potential of hemp.
CV Sciences (CVSI) is both a researcher into CBD-based medicines and a producer of consumer food products based on that research. It is tapping into a wide range of market sectors through products such as its Purified Liquids products for vaping. Its PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry.
On the agricultural side, Terra Tech (TRTC) is a vertically integrated, cannabis-focused company committed to cultivating and providing the highest quality medical cannabis. Its research-led approach to cultivating and cross-breeding marijuana strains leads to better products for treating a wide range of ailments. Its greenhouse and hydroponic systems allow the safe, efficient growth of cannabis and other plants in urban farming facilities, expanding the options for production in the CBD industry.
With the wider CBD industry growing, companies such as ChineseInvestors.com are aiming to profit from the growing power of hemp and its legal position in a disputed market.
For more information on ChineseInvestors.com, visit: ChineseInvestors.com (CIIX)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
NetworkNewsWire Editorial Coverage: With the rapid growth of the legal American cannabis market, other cannabidiol (CBD)-based products are often overlooked. In particular, hemp has the opportunity to reach medical and nutritional customers that cannabis can’t, and ChineseInvestors.com (CIIX) (CIIX Profile) is tapping into that market. With the potential to provide similar benefits without the same restrictions, hemp products can be sold in markets such as China, where cannabis remains illegal. It’s a part of the market that CBD industry leaders such as Freedom Leaf, Inc. (FRLF) are also catering to, with marketing and media products for hemp companies. Medical Marijuana, Inc. (MJNA), America’s first publicly traded cannabis company, is carrying its CBD business beyond the United States and across the Americas, while CV Sciences, Inc. (CVSI) combines scientific research with a consumer products division to bring innovative CBD products to the market. At the farming end of the supply chain, Terra Tech Corp. (TRTC) provides advanced agricultural solutions and new, better strains of cannabis for a growing market.
The Growing Cannabidiol Market
The market for legal marijuana is growing at an ever-accelerating rate. Recent research by Arcview Market Research and BDS Analytics indicates that sales in North America reached almost $10 billion in 2017 and are expected to reach $24.5 billion by 2021 as more markets are created for both medical and recreational use. But this is still a sector threatened by great uncertainties and…
Read more »
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Source: NetworkNewsWire (February 8, 2018 – 9:00 AM EST)
PHOENIX, Feb. 08, 2018 — India Globalization Capital, Inc. (NYSE American:IGC) (the “Company”) provides IGC operations update on Stock Day Podcast with Everett Jolly.
IGC has a legacy business in infrastructure focused primarily in India, Malaysia and Hong Kong. More recently the company has expanded into the Cannabis Pharmacy business, which will reach the United States and Canada.
“The diversification in IGC both geographically and by industry makes it an interesting investment,” said Jolly. “The cannabis industry is rapidly growing in the United States; the Company’s decision to direct their attention to one specific area of study, Alzheimer’s, will allow parallel penetration into the industry.”
Mukunda commented, “We are preparing to release our first product, Hyalolex, through dispensaries in the next several weeks. In parallel we are also pursuing a traditional FDA path that is in its pre-clinical phase. Our product is the result of many years of research and I look forward to the positive effects it will have on Alzheimer’s patients.”
To view the interview in its entirety, click here: https://upticknewswire.com/featured-interview-ceo-ram-mukunda-of-india-globalization-capital-inc-nasdaq-igc/
About IGC
IGC has two lines of business, a legacy infrastructure and commodity trading business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients. The Company recently announced that it is working on using blockchain to address issues specific to the cannabis industry including transactional difficulties, product labeling, product identification assurance (PIA), and product origin assurance (POA). The Company is based in Maryland, USA.
For more information please visit www.igcpharma.com
Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick.
Follow us and keep an eye on Uptick’s YouTube, Twitter, and Facebook for additional radio and video shows produced by Uptick! https://www.youtube.com/watch?v=kU5SVLp4org
Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit India Globalization Capital’s message board on: https://investorshangout.com/India-Globalization-Capital-Inc-IGC-56759/
Forward-looking Statements
Please see forward looking statements as discussed in detail in IGC’s Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.
Contact:
Claudia Grimaldi
301-983-0998
–ALSO TODAY–
India Globalization’s Hyalolex Shows Promise in Treating Patients with Alzheimer’s Disease — CFN Media
Seattle, WA, Feb. 08, 2018 — CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering India Globalization Capital Inc’s (NYSE American: IGC) Hyalolex, a cannabinoid-based therapy that appears to act on many different hypotheses of disease modalities. Investors interested in the AD space may want to take a closer look at the stock.
Alzheimer’s disease has already become the sixth leading cause of death in the United States and could cost the healthcare system upwards of $1 trillion by 2050. While pharmaceutical companies have spent billions of dollars trying to cure the disease, experts still aren’t sure exactly what causes the condition and how to go about treating it. The good news is that there are some therapeutics that act on multiple potential underlying causes.
Elusive Alzheimer’s Treatments
Alzheimer’s disease affects over five million people in the United States and has become the sixth leading cause of death. Last year, the disease and related dementias cost the country $260 billion and is projected to cost about $1.1 trillion by 2050. It is America’s most expensive disease. About 10% of people over 65 are diagnosed with Alzheimer’s, and almost 66% of Alzheimer’s patients are women. At the same time, 35% of caregivers report that their health has gotten worse due to their care responsibilities, adding even further to the costs associated with the disease.
While there are several drugs that treat Alzheimer’s disease, the quest to cure the illness has frustrated even the largest pharmaceutical companies. The consensus for the past 25 years has been that the disease is caused by the build-up of a sticky plaque called beta amyloid in the brain. Billions of dollars were subsequently spent developing drugs to clear beta amyloid, but all of them have failed at various stages of clinical trials.
Some companies are shifting their focus to tau proteins, which get twisted and block the internal transport system of neurons. While one clinical trial focused on these proteins failed, the research remains in the early stages of clinical trials. Other researchers believe that over-reactive oxygen molecules are causing oxidative stress, which could lead to the build-up of beta amyloid plaque and other “symptoms” of the disease.
How Cannabis Could Help
India Globalization Capital’s Hyalolex (IGC-AD1) has been shown to act on many of these different pathways in early research studies. In addition to modulating beta amyloid production and inhibiting aggregation, the compound appears to inhibit hyperphosphorylation of tau proteins, enhance mitochondrial function, and modulate several endpoints of AD. The compound is also non-toxic to neurons and doesn’t product a “high” feeling.
Using an immunoblotting technique, Dr. Chuanhai Cao demonstrated that IGC-AD1 inhibits beta amyloid aggregation in a dose-dependent manner by increasing monomer levels. This addresses the “amyloid hypothesis” that states that the aggregation of amyloids into toxic oligomers is a key pathogenic event in the onset of AD. These plaques could also trigger other pathological events, such as oxidative damage and inflammation.
The same technique of using immunoblotting showed that IGC-AD1 reduced the expression of an enzyme that enables phosphorylation by as much as 53% to 62%, which reverses some of the pathological effects of overexpressed APP and tau proteins. This addresses the “tau protein hypothesis” that states that tau protein phosphorylation is three to four times higher than a normal brain, which could be the underlying cause of AD.
Finally, Dr. Cao showed that IGC-AD1 enhanced mitochondrial function by between 30% and 60%, which could address the “mitochondrial cascade hypothesis”. This hypothesis is based on the notion that mitochondrial dysfunction – which worsens with age naturally – could start a cascade that ultimately leads to the disease. Evidence has also shown that elevated beta amyloid levels contribute to these mitochondrial abnormalities.
Other than the evidence showing that Hyalolex may address the three disease etiological hypothesis as outlined above, Hyalolex at larger doses may reduce patient anxiety, patient aggression, sleep disorder and alleviate overall caregiver distress.
Commercialization Strategy
Hyalolex is a liquid formulation that comprises of cannabis extracts, including THC, along with other natural compounds. It will be prescribed in two different doses. The smaller dose for mild to moderate AD patients, and the larger dose for moderate to advanced patients. IGC plans to distribute its technology through licensed medical cannabis dispensaries in the United States. This process will include state-by-state sourcing, formula assembly, packaging, and distribution utilizing best practices to ensure quality control while complying with the current legal guidelines established by each individual state.
Management plans to begin the rollout in the first half of this year in Washington D.C., Maryland, and California dispensaries. To help facilitate the rollout, the company engaged The Medical Marketing Group inc., a provider of outsourced product-detailing, education, and outreach services. The company projects the rollout of Hyalolex in 10 of the 29 legal states in 2018.
In addition to its launch across dispensaries, the company is preparing the groundwork necessary for Phase 2B human trials with the U.S. Food and Drug Administration (FDA). The company’s most recent results showed compelling in vivo data from genetically engineered mice, including marked 50% improvement in spatial memory. If these results translate to humans, the drug program could be groundbreaking within the industry.
Please follow the link to read the full article:
http://www.cannabisfn.com/india-globalizations-hyalolex-shows-promise-treating-patients-alzheimers-disease/
For more information, visit the company’s website at http://www.igcinc.us/.
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Contact:
CFN Media
Frank Lane
206-369-7050
flane@cannabisfn.com
Doral, FL, Feb. 08, 2018 — Earth Science Tech, Inc. (OTC PINK: ETST) (“ETST” or the “Company”), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announced launch date for the Company’s highly-anticipated, revamped industrial hemp Cannabidiol (CBD) products, which lead to forecast updates reflecting to a record-high monthly revenue.
February 13, 2018 is the official launch date for the Company’s highly anticipated High Grade Full Spectrum Cannabinoids product, and corresponding marketing strategy, announced early December 2017.
High Grade Full Spectrum Cannabinoids is composed of European CO2, supercritical extracted, organically grown, and unfiltered industrial hemp. The Company was originally planning on using American industrial hemp but was able to secure a reliable high-quality source in Europe to continue offering European industrial hemp, which led to slight delays from the original launch time frame. ETST will be one of the first companies to market its industrial hemp product as a Cannabinoid Complex instead of CBD, disclosing the milligrams (mg) of each Cannabinoid (CBD, CBDV, CBG, CBC, CBN, & CBDA). Cannabinoid complex is naturally occurring in the industrial hemp plant used, and is rich in Terpenes, and Saponins. Mixed, bottled, and packaged in the U.S. at a CGMP facility, the Company’s High Grade Full Spectrum Cannabinoids offer the highest therapeutic quality that current end-users trust and carry forward. Preorders are currently being accepted online.
Since last year’s announcement on product and marketing strategy revamp, Mr. Checkout distributor launched last week, and new veteran Chef Sales Officer, (CSO), the exponential demand increase has led the Company to revise forecasts to reflect what is anticipated to be the highest revenue month to date. The Company has new chain stores, clinics, and health shops eagerly waiting for the official launch to place their initial orders.
Nickolas S. Tabraue, ETST’s president, director and COO concludes, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor Mr. Checkout, we are on track for a record-setting revenue month. We’ve made clear that we intend to make 2018 our breakout year, and we are laying a strong foundation in this first quarter. We will continue to provide updates on our material events as we can.”
“While much of the up-listing and Reg A+ offering processes are out of our hands, we want to reassure our shareholders that we have worked hard to prepare the required paperwork for our audit and offering filings. We are prioritizing transparency and creating lasting value for our stakeholders and are committed to up-listing to the QB tier of the OTC Markets this year. We will provide updates as progress is made.”
About Earth Science Tech, Inc. (ETST): Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil.
To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com
About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (sexually transmitted infections and/or diseases). Earth Science Pharmaceutical CEO Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.
To learn more please visit: www.EarthSciencePharmaceutical.com
About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals, as well as other products & solutions. Cannabis Therapeutics’ mission it to help change the health care landscape by introducing its proprietary cannabis-cannabinoid-based products made for both the pharmaceutical and retail consumer markets worldwide.
To learn more please visit: www.CannabisThera.com
About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.
To learn more please visit: www.KannaBidioiDInc.com
SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Dave Demarest (305) 546-7640
Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305) 615-2118
NEW YORK, Feb. 08, 2018 — via NetworkWire – Pivot Pharmaceuticals Inc. (OTCQB:PVOTF), an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies, announces that it has engaged the corporate communications expertise of NetworkNewsWire (“NNW”).
“Pivot’s key competitive advantages include cannabis formulation and delivery technologies, scientific and regulatory expertise, product sales and distribution experience, and our ability to work with best-in-class global partners,” Pivot CEO Dr. Patrick Frankham said. “We continue to create shareholder value by building a sustainable, long-term company that is well positioned in the fast-changing cannabis industry.”
NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with Pivot Pharmaceuticals Inc., NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.
“Pivot Pharmaceuticals is preparing to commercialize an industry leading pipeline of cannabinoid-based consumer healthcare products,” states Sherri Franklin, director of Content Marketing for NNW. “We look forward to assisting the company with a corporate communications campaign that effectively keeps shareholders and the investment community up to date on its operations and technology.”
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
MarketNewsUpdates.com News Commentary
Palm Beach, FL – (February 8, 2018) – The way consumers globally pay is changing. As shopping habits evolve, e-commerce and m-commerce methods such as in-app and one-click ordering are becoming increasingly popular. In addition, the exponential growth of the Internet of Things (IoT) is introducing a wealth of new payment use-applications. The promise of frictionless, secure transactions in real time from any payment device (be it a kiosk, smartphone, computer or payment terminal) is one that gives the consumer complete control over their purchasing experience. Electronic wallets and mobile ecommerce are continually gaining popularity due to rise of easy to use mobile apps while the market is driven by tech firms introducing new and secure devices & applications and by banks developing their own apps and providing on the go services for the customers. Active companies in the markets this week include Gopher Protocol Inc. (OTC: GOPH), Net Element, Inc. (NASDAQ: NETE), PayPal Holdings, Inc. (NASDAQ: PYPL), Alibaba Group Holding Limited (NYSE: BABA), Apple Inc. (NASDAQ: AAPL).
Gopher Protocol Inc. (OTCQB: GOPH), a development-stage company which specializes in the creation of Internet of Things (IoT) and Artificial Intelligence enabled mobile technologies, incorporates UGopherServices Limited in England and Wales.
With the incorporation of UGopherServices Limited, Gopher looks to expand its platform internationally. Since Gopher’s acquisition of RWJ Marketing’s assets and the incorporation of UGopherServices Corp. in the United States, Gopher has been approached by potential partners to provide services to international clientele. In order to maximize this international opportunity and shareholder value, Gopher established UGopherServices Limited, which was incorporated in England and Wales and will operate as a wholly owned subsidiary.
“We are looking to initially introduce our existing product and service offerings to clients internationally. As we further develop our offerings, such as an electronic wallet, in the United States we, we intend to offer these products internationally as well assuming there is a suitable fit” stated Gopher CEO Greg Bauer. Read this and more news for GOPH at: http://www.marketnewsupdates.com/news/goph.html
In other Mobile Payments and Digital Commerce developments in the markets this week:
Net Element, Inc. (NASDAQ: NETE), a global technology and value-added solutions group, this week launched its newest multi-channel payments platform, Netevia. Connecting and simplifying payments across sales channels through a single integration point, Netevia delivers end-to-end payment processing through easy-to-use APIs. This model complements Net Element’s ability to perform in a multi-channel environment, including point-of-sale (POS), e-commerce, mobile devices and will enable the company to perform in blockchain technology solutions.
A recent article on PYMNTS.com, PayPal’s “Global Freelancer Insights Report” found that mobile is an important tool for freelancers, while security is also top of mind. In a corporate blog post detailing the results, PayPal Holdings, Inc. (NASDAQ: PYPL) said mobile payments, mobile apps and mobile communication are important tools for freelancers, with those surveyed noting mobile tools and the ability to invoice and receive payments on mobile devices is crucial for them. Additionally, PayPal said security is a big concern for freelancers, with 47 percent of those surveyed saying security is an important factor when choosing a payment method. While PayPal’s survey found freelancers to be optimistic about their futures, they did admit an irregular income is their biggest challenge. Of the survey respondents, the majority of freelancers around the world expect business to grow in the future, with strong growth expected from those residing in Vietnam, India, the Philippines, Mexico and Argentina. At the same time, more than 50 percent of freelancers polled in Hong Kong, Russia and South Africa said irregular payments are an issue. Read the full article at: https://www.pymnts.com/news/mobile-payments/2018/paypal-freelancer-jobs-platforms/
MacRumors.com reported this week that Alipay, the mobile payment system offered by Chinese e-commerce giant Alibaba Group Holding Limited (NYSE: BABA), will soon be accepted in Apple retail stores across China, making it the first third-party mobile payment system to be accepted at brick-and-mortar Apple stores anywhere in the world (via Reuters). The partnership with Apple Inc. (NASDAQ: AAPL) was announced in a statement on Wednesday by Alibaba affiliate Ant Financial, which runs Alipay. Apple’s regional China website, iTunes Store, and App Store have accepted Alipay for over a year, but Apple has now agreed to accept Alipay payments across all of its 41 local retail stores in the country, where Apple Pay has thus far received a lukewarm reception. Read more at: https://www.macrumors.com/2018/02/07/apple-retail-stores-china-alipay-mobile-payments/
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated twenty three hundred dollars for news coverage of the current press releases issued by Gopher Protocol Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information:
Media Contact email: info@marketnewsupdates.com – +1(561)325-8757
